Is Thymosin Alpha-1 Legal in Ohio? How to Access It Legally

HealthRX.com

Thymosin alpha-1 is not FDA-approved or on pharmacy bulk lists

Print or save as PDF

  • FDA status / Not approved; no US application on file [1]
  • Approved abroad / Italy, India and Hong Kong [1]
  • Pharmacy bulk list / In none of the three categories [2]
  • Outsourcing-facility list / Category 3, nominated without adequate support [3]
  • FDA advisory vote / 4 yes, 17 no, December 2024 [4]
  • HHS peptide draft / Not among the six peptides named [6]

What Is FDA's Position on Thymosin Alpha-1?

A search of Drugs@FDA returns no US application for thymosin alpha-1, also called thymalfasin, and FDA's December 2024 review notes four US orphan drug designations, which are not approvals [1]. It is an approved medicine elsewhere: FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].

On FDA's list for state-licensed pharmacies, updated May 14, 2026, thymosin alpha-1 appears in none of the three categories, and the category 1 policy does not apply to it [2]. On the list for outsourcing facilities, updated March 21, 2025, it is in category 3, 'nominated without adequate support' [3]. FDA's Pharmacy Compounding Advisory Committee voted on December 4, 2024: 4 yes and 17 no, with no abstentions, on both the free base and the acetate, and FDA proposed that it not be added to the pharmacy list [4]. It is not among the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6]. It also sits in the 'nominated but withdrawn' table of bulk substances that may present significant safety risks, with FDA's concerns still posted: significant immunogenicity risk for certain routes of administration, peptide-impurity and characterization problems, and safety information FDA called inadequate to understand the extent of any safety issues [7].

Questions worth asking

Choose the questions you want to keep

What Does Ohio Law Add?

Ohio Revised Code 4743.09 requires each health care professional licensing board to permit the professionals it licenses to provide telehealth services, and it lists physicians, advanced practice registered nurses, physician assistants and pharmacists among them [5]. Ohio Revised Code 4731.22 lists grounds on which the State Medical Board of Ohio may limit, revoke or suspend a license, including failure to maintain minimal standards applicable to the selection or administration of drugs, and prescribing or administering drugs for other than legal and legitimate therapeutic purposes [8]. Neither provision, as described here, names thymosin alpha-1.

What Do the Trials Show?

A 2026 Cochrane review of thymosin alpha-1 for chronic hepatitis B pooled 10 randomized trials, 1,349 adults, published 1991 to 2018 [9]. It found possible lower all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, little to no effect on quality of life or liver histology, and the reviewers said they are 'not sure' thymosin alpha-1 helps [9]. On harms, it may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) [9]. An FDA search of its adverse-event database on April 22, 2024 returned zero reports for the peptide [1].

What Dose Is Used Where It Is Approved?

There is no US-approved dose [1]. The Italian Zadaxin label directs 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. That label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1]. Zadaxin is the finished 1.6 mg vial sold outside the US and is not interchangeable with bulk thymosin alpha-1 powder [1].

Is thymosin alpha-1 legal in Ohio?
It is not FDA-approved, FDA proposed against adding it to the pharmacy bulk-substances list after a 4 to 17 advisory committee vote, and the category 1 compounding policy does not apply to it [1][2][4]. The Ohio telehealth and medical-board provisions discussed on this page do not name it [5][8].
Can an Ohio pharmacy compound thymosin alpha-1?
It appears in none of the three categories on FDA's list for state-licensed pharmacies, so the category 1 policy does not cover it, and on the outsourcing-facility list it is category 3, nominated without adequate support [2][3].
Is thymosin alpha-1 approved in any country?
Not in the United States, where Drugs@FDA shows no application and four orphan designations fall short of approval [1]. FDA lists approvals in Italy, India and Hong Kong [1].
Does thymosin alpha-1 work?
A 2026 Cochrane review of 10 trials in 1,349 adults with chronic hepatitis B found possible lower all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96; very low certainty) and little to no effect on quality of life or liver histology; the reviewers said they are not sure it helps [9].
Show all 9 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Ohio? How to Access It Legally